article
Oncology advances through the lens of women in STEM
Dr Pooja Hingorani opens up about her journey in oncology research, the obstacles she’s overcome as a woman in STEM, and her mission to transform cancer care.
List view / Grid view
Clinical Trials
news
NKTR-255 shows positive results in lymphoma therapy
Nektar Therapeutics' NKTR-255 improves CAR-T therapy outcomes in lymphoma patients. Find out how this development could impact cancer treatment.
article
New targeted therapies show promise in lung cancer treatment
Recent advancements in targeted therapies and immunotherapies are transforming lung cancer treatment. Discover how these innovations are improving outcomes and providing hope for patients.
news
Novartis licenses innovative treatment for Huntington’s disease
Novartis has teamed up with PTC Therapeutics to develop PTC518, a groundbreaking treatment that targets the cause of Huntington's disease, offering new hope for patients.
news
Eurofins expands to China to strengthen local expertise
Eurofins Healthcare Assurance is expanding into China to better serve key industries with local expertise. This move strengthens their commitment to quality assurance and regulatory services on a global scale.
news
Breakthrough trial offers new hope for cystic fibrosis patients
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
article
Women in STEM with Avideh Nazeri
Avideh Nazeri, Vice President of Clinical, Medical and Regulatory for Novo Nordisk UK, reflects on her journey through the world of STEM, highlighting the resilience and determination required to overcome biases and challenges along the way. She discusses how perseverance, collaboration and independent thinking have shaped her career, and offers…
news
Developing the world’s first ovarian cancer prevention vaccine
Cancer Research UK-funded researchers aim to identify targets for an ovarian cancer vaccine, which could prevent the disease at an early stage.
article
Drug candidates with blockbuster potential for CNS diseases
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
article
Rapid delivery of toxicological material
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, explains Alejandro Fernandez Martell and James Berrie from Lonza.
article
’1104: tackling the root cause of allergic disease
In this Q&A, Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions. We delve into its unique mechanism of action, supported by preclinical and clinical findings.…
news
Transforming disease diagnosis with new nanoparticles
A new class of RNAs packed into extracellular vesicles have potential as biomarkers for prostate cancer and other diseases.
news
Ketogenic diet and a new cancer drug starves pancreatic cells
The discovery that eFT508 blocks eIF4E and the ketogenic pathway could provide the foundation for personalised therapies.
news
Type 1 regulatory cells limit immunotherapy success
Scientists discovered the number of Tr1 cells increased as tumours grew larger, making mice insensitive to immunotherapy.
article
Out of the lab and into patients: targeting APE1/Ref-1
We had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at PharmSci 360 in 2024. He elucidates what makes…
